Using stem cells to repair damaged heart tissue is a promising, but complex area of research. Dr. McAlpine’s research aims to take a significant step forward by creating a "4D printed" system to deliver the biochemicals that tell stem cells where to go, when to grow, and what kind of cells to develop into so that they can regenerate specific kinds of tissues in the heart in an orchestrated manner.

This grant is in no-cost extension.

Interim report:

Dr. Devaux is testing a new way of making human blood cells go back to a state from which they can then develop into other kinds of cells, particularly insulin-producing cells that could help diabetic patients

Grant is in no-cost extension through 8/30/2019.

Year 1 Progress Report:

The overall objective of this proposal is to conduct a multi-site, placebo-controlled Phase IIA clinical trial to obtain clinical data on the safety, efficacy and mechanism of action of intrathecal injection of adipose-derived mesenchymal stem cells as a regenerative therapy for the treatment of the incurable condition, amyotrophic lateral sclerosis.

Read Staff’s most recent interim report here

The goal of this Phase I study is to establish the safety and feasibility of intramyocardial injection of autologous bone marrow derived mononuclear cells (BM-MNC) into the myopathic right ventricle of patients with Ebstein anomaly (EA) at time of elective cardiac surgery.

In no-cost extension to enroll additional patients in study

Read Holst’s most recent NCE Interim Progress Report here